TransMedics (TMDX) Cost of Revenue (2018 - 2026)

TransMedics has reported Cost of Revenue for 9 years, with the latest figure at $76.8 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 26.27% year-over-year to $76.8 million in Q2 2026; TTM through Jun 2026 was $276.1 million, a 29.26% increase from a year earlier, with the FY2025 full-year figure at $242.7 million, up 35.23% from the prior year.
• Cost of Revenue was $76.8 million for Q2 2026 at TransMedics, up from $72.8 million in the prior quarter.
• The five-year high for Cost of Revenue was $76.8 million in Q2 2026, with the low at $3.8 million in Q1 2022.
• Average Cost of Revenue over 5 years is $38.2 million, with a median of $41.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue surged 373.89% in 2022, then advanced 23.65% in 2025.
• Over 5 years, Cost of Revenue stood at $10.7 million in 2022, then surged by 211.56% to $33.2 million in 2023, then soared by 49.21% to $49.6 million in 2024, then jumped by 35.76% to $67.4 million in 2025, then increased by 13.96% to $76.8 million in 2026.
• The last three Cost of Revenue figures came in at $76.8 million (Q2 2026), $72.8 million (Q1 2026), and $67.4 million (Q4 2025), per Business Quant data.